The pharmacological treatment of primary aldosteronism

Bibliography

• STEWART PM: Mineralocorticoid hypertension. Lancet (1999) 353:1341-1347.
   PubMed Web of Science ®Google Scholar
• FARDELLA CE, MOSSO L, GOMEZ-SANCHEZ C et al.: Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J. Clin. Endocrinol. Metab. (2000) 85:1863-1867.
   PubMed Web of Science ®Google Scholar
• MOSSO L, CARVAJAL C, GONZALEZ A et al.: Primary aldosteronism and hypertensive disease. Hypertension (2003) 42:161-165.
   PubMed Web of Science ®Google Scholar
• LIM PO, RODGERS P, CARDALE K, WATSON AD, MACDONALD TM: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet (1999) 353:40.
   PubMed Web of Science ®Google Scholar
• MULATERO P, STOWASSER M, LOH KC et al.: Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J. Clin. Endocrinol. Metab. (2004) 89:1045-1050.
   PubMed Web of Science ®Google Scholar
• GANGULY A: Primary aldosteronism. N. Engl. J. Med. (1998) 339:1828-1834.
   PubMed Web of Science ®Google Scholar
• YOUNG WF JR: Minireview: primary aldosteronism – changing concepts in diagnosis and treatment. Endocrinology (2003) 144:2208-2213.
   PubMed Web of Science ®Google Scholar
• FOO R, O’SHAUGHNESSY KM, BROWN MJ: Hyperaldosteronism: recent concepts, diagnosis, and management. Postgrad. Med. J. (2001) 77:639-644.
   PubMedGoogle Scholar
• GHOSE RP, HALL PM, BRAVO EL: Medical management of aldosterone-producing adenomas. Ann. Intern. Med. (1999) 131:105-108.
   PubMedGoogle Scholar
• LIM PO, YOUNG WF, MACDONALD TM, STOWASSER M: A review of the medical treatment of primary aldosteronism. J. Hypertens. (2001) 19(3):353-361.
   PubMed Web of Science ®Google Scholar
• QUINKLER M, LEPENIES J, DIEDERICH S: Primary hyperaldosteronism. Exp. Clin. Endocrinol. Diabetes (2002) 10(6):263-271.
   Google Scholar
• ROSSI G, BOSCARO M, RONCONI V, FUNDER JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol. Metab. (2005) 16:104-107.
   PubMedGoogle Scholar
• CONNELL JMC, DAVIES E: The new biology of aldosterone. J. Endocrinol. (2005) 186:1-20.
   PubMed Web of Science ®Google Scholar
• FUNDER JW: The nongenomic actions of aldosterone. Endocr. Rev. (2005) 26:313-321.
   PubMedGoogle Scholar
• LOSEL R, SCHULTZ A, WEHLING M: A quick glance at rapid aldosterone action. Mol. Cell. Endocrinol. (2004) 217:137-141.
   PubMedGoogle Scholar
• NISHIMURA M, UZU T, FUJII T et al.: Cardiovascular complications in patients with primary aldosteronism. Am. J. Kidney Dis. (1999) 33:261-266.
   PubMed Web of Science ®Google Scholar
• MILLIEZ P, GIRERD X, PLOUIN PF, BLACHER J, SAFAR ME, MOURAD JJ: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. (2005) 45:1243-1248.
   PubMed Web of Science ®Google Scholar
• STRUTHERS AD: Aldosterone blockade in cardiovascular disease. Heart (2004) 90:1229-1234.
   PubMed Web of Science ®Google Scholar
• BROWN NJ: Aldosterone and end-organ damage. Curr. Opin. Nephrol. Hypertens. (2005) 14:235-241.
   PubMed Web of Science ®Google Scholar
• EPSTEIN M: Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J. Hypertens. (2001) 19:829-842.
   PubMed Web of Science ®Google Scholar
• STIER CT, ROCHA R, CHANDER PN: Effect of aldosterone and MR blockade on the brain and the kidney. Heart Failure Reviews (2005) 10:53-62.
   PubMed Web of Science ®Google Scholar
• WELLHOENER P, BORN J, FEHM HL, DODT C: Elevated resting and exercise-induced cortisol levels after mineralocorticoid receptor blockade with canrenoate in healthy humans. J. Clin. Endocrinol. Metab. (2004) 89:5048-5052.
   PubMedGoogle Scholar
• VASAN RS, EVANS JC, LARSON MG et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N. Engl. J. Med. (2004) 351:33-41.
   PubMed Web of Science ®Google Scholar
• PITT B, REICHEK N, WILLENBROCK R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation (2003) 108:1831-1838.
   PubMed Web of Science ®Google Scholar
• SHIGEMATSU Y, HAMADA M, OKAYAMA H et al.: Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension (1997) 29:723-727.
   PubMedGoogle Scholar
• EPSTEIN M, BUCKALEW JV, MARTINEZ F et al.: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria. Am. J. Hypertens. (2002) 15:A24.
   PubMed Web of Science ®Google Scholar
• PITT B, ZANNAD F, REMME WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N. Engl. J. Med. (1999) 341:709-717.
   PubMed Web of Science ®Google Scholar
• PITT B, REMME W, ZANNAD F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. (2003) 348:1309-1321. Erratum in: N. Engl. J. Med. (2003) 348(22):2271.
   PubMed Web of Science ®Google Scholar
• MENARD J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol. Cell. Endocrinol. (2004) 217:45-52.
   PubMed Web of Science ®Google Scholar
• GORDON RD, LARAGH JH, FUNDER JW: Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol. Metab. (2005) 16:108-113.
   PubMed Web of Science ®Google Scholar
• MONTORI VM, YOUNG WF JR: Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary aldosteronism. A systematic review of the literature. Endocrinol. Metab. Clin. North Am. (2002) 31:619-632.
   PubMed Web of Science ®Google Scholar
• MULATERO P, RABBIA F, MILAN A et al.: Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension (2002) 40:897-902.
   PubMed Web of Science ®Google Scholar
• BERNINI G, MORETTI A, ARGENIO G, SALVETTI A: Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur. J. Endocrinol. (2002) 146:523-529.
   PubMedGoogle Scholar
• MULATERO P, DLUHY RG, GIACCHETTI G, BOSCARO M, VEGLIO F, STEWART PM: Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol. Metab. (2005) 16:114-119.
   PubMed Web of Science ®Google Scholar
• HARRIS DA, AU-YONG I, BASNYAT PS, SADLER GP, WHEELER MH: Review of surgical management of aldosterone secreting tumours of the adrenal cortex. Eur. J. Surg. Oncol. (2003) 29:467-474.
   PubMed Web of Science ®Google Scholar
• DLUHY RG, LIFTON RP: Glucocorticoid-remediable aldosteronism. J. Clin. Endocrinol. Metab (1999) 84:4341-4344.
   PubMed Web of Science ®Google Scholar
• JACKSON RV, LAFFERTY ANTH, TORPY DJ, STRATAKIS CONS: New genetic insights in familial hyperaldosteronism. Ann. NY Acad. Sci. (2002) 970:77-88.
   PubMedGoogle Scholar
• YOUNG WF, STANSON AW, THOMPSON GB, GRANT CS, FARLEY DR, VAN HEERDEN JA: Role for adrenal venous sampling in primary aldosteronism. Surgery (2004) 136:1227-1235.
   PubMed Web of Science ®Google Scholar
• ROSSI GP, SACCHETTO A, CHIESURA-CORONA M et al.: Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J. Clin. Endocrinol. Metab. (2001) 86:1083-1090.
   PubMed Web of Science ®Google Scholar
• BROWN JJ, DAVIES DL, FERRIS JB et al.: Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess and low plasma renin. Br. Med. J. (1972) 2:729-734.
   PubMed Web of Science ®Google Scholar
• ROSSI GP, SACCHETTO A, PAVAN E et al.: Remodeling of the left ventricle in primary aldosteronism due to conn’s adenoma. Circulation (1997) 95:1471-1478.
   PubMed Web of Science ®Google Scholar
• SYWAK JLP: Long-term follow-up and cost benefit of adrenalectomy in patients with primary hyperaldosteronism. Br. J. Surg. (2002) 89:1587-1593.
   PubMed Web of Science ®Google Scholar
• SAWKA AM, YOUNG WF JR, THOMPSON GB et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. (2001) 135:258-261.
   PubMed Web of Science ®Google Scholar
• FERRIS JB, BEEVERS DG, BODDY K et al.: The treatment of low renin (primary) hyperaldosteronism. Am. Heart J. (1978) 96:97-109.
   PubMedGoogle Scholar
• COHN JN, KOWEY PR, WHELTON PK, PRISANT LM: New guidelines for potassium replacement in clinical practice: a contemporary review by the national council on potassium in clinical practice. Arch. Intern. Med. (2000) 160:2429-2436.
   PubMed Web of Science ®Google Scholar
• DELYANI JA: Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int. (2000) 57:1408-1411.
   PubMed Web of Science ®Google Scholar
• GARTHWAITE SM, MCMAHON EG: The evolution of aldosterone antagonists. Mol. Cell. Endocrinol. (2004) 217:27-31.
   PubMed Web of Science ®Google Scholar
• RAMIRES FJ, MANSUR A, COELHO O et al.: Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am. J. Cardiol. (2000) 85:1207-1211.
   PubMed Web of Science ®Google Scholar
• JEUNEMAITRE X, CHATELLIER G, KREFT-JAIS C et al.: Efficacy and tolerance of spironolactone in essential hypertension. Am. J. Cardiol. (1987) 60:820-825.
   PubMed Web of Science ®Google Scholar
• BEEVERS DG, BROWN JJ, FERRISS JB, FRASER R, LEVER AF, ROBERTSON JIS: The use of spironolactone in the diagnosis and the treatment of hypertension associated with mineralocorticoid excess. Am. Heart J. (1973) 86:404-414.
   PubMedGoogle Scholar
• SICA DA: Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Failure Reviews (2005) 10:23-29.
   PubMed Web of Science ®Google Scholar
• LIM PO, JUNG RT, MACDONALD TM: Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br. J. Clin. Pharmacol. (1999) 48:756-760.
   PubMed Web of Science ®Google Scholar
• BLUMENFELD JD, LARAGH JH: Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am. J. Hypertens. (1998) 11:894-896.
   PubMedGoogle Scholar
• ESPINER EA, ROSS DG, YANDLE TG, RICHARDS AM, HUNT PJ: Predicting surgically remedial primary aldosteronism: role of adrenal scanning, posture testing, and adrenal vein sampling. J. Clin. Endocrinol. Metab. (2003) 88:3637-3644.
   PubMedGoogle Scholar
• SAWKA AM, YOUNG WF, THOMPSON GB et al.: Primary aldosteronism: factors associated with normalization of blood pressure after surgery. Ann. Intern. Med. (2001) 135:258-261.
   PubMed Web of Science ®Google Scholar
• DERUELLE P, DUFOUR P, MAGNENANT E, COUROUBLE N, PUECH F: Maternal Bartter’s syndrome in pregnancy treated by amiloride. Eur. J. Obstet. Gynecol. Reprod. Biol. (2004) 115:106-107.
   PubMed Web of Science ®Google Scholar
• LINDSAY JR, NIEMAN LK: Adrenal disorders in pregnancy. Endocrinol. Metab. Clin. North Am. (2006) 35:1-20.
   PubMed Web of Science ®Google Scholar
• ARMANINI D, SCARONI C, MATTARELLO MJ, FIORE C, ALBIGER N, SARTORATO P: Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. J. Endocrinol. Invest. (2005) 28:236-240.
   PubMedGoogle Scholar
• DUPONT A: Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet (1985) 2:731.
   PubMedGoogle Scholar
• JOINT NATIONAL COMMITTEE: British National Formulary, 49th edn. British Medical Association and Royal Pharmaceutical Society, London (2005).
   Google Scholar
• LIEW D, KRUM H: Aldosterone receptor antagonists for hypertension. What do they offer? Drugs (2003) 63:1963-1972.
   PubMed Web of Science ®Google Scholar
• WEINBERGER MH, RONIKER B, KRAUSE SL, WEISS RJ: Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am. J. Hypertens. (2002) 15:709-716.
   PubMed Web of Science ®Google Scholar
• LEVY DG, ROCHA R, FUNDER JW: Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. (2004) 89:2736-2740.
   PubMed Web of Science ®Google Scholar
• ZILLICH AJ, CARTER BL: Eplerenone – a novel selective aldosterone blocker. Ann. Pharmacother. (2002) 36:1567-1576.
   PubMedGoogle Scholar
• STOWASSER M, BACHMANN AW, HUGGARD PR, ROSSETTI TR, GORDON RD: Treatment of familial hyperaldosteronism Type I: only partial suppression of adrenocorticotropin required to correct hypertension. J. Clin. Endocrinol. Metab. (2000) 85:3313-3318.
   PubMedGoogle Scholar
• GRIFFING GT, COLE AG: Amiloride in primary hyperaldosteronism. Clin. Pharmacol. Ther. (1982) 31:56-61.
   PubMedGoogle Scholar
• GANGULY A, WEINBERGER MH: Triamterene-thiazide combination: alternative therapy for primary aldosteronism. Clin. Pharmacol. Ther. (1981) 30:246-250.
   PubMedGoogle Scholar
• NADLER JL, HSUEH W, HORTON R: Therapeutic effect of calcium channel blockade in primary aldosteronism. J. Clin. Endocrinol. Metab. (1985) 60:896-899.
   PubMed Web of Science ®Google Scholar
• BRAVO EL: Medical management of primary hyperaldosteronism. Curr. Hypertens. Rep. (2001) 3:406-409.
   PubMedGoogle Scholar
• MANTERO F, FALLO F, OPOCHER G, ARMANINI D, BOSCARO M, SCARONI C: Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin. Sci. (1981) 61(Suppl. 7):289s-293s.
   PubMed Web of Science ®Google Scholar
• ATKINSON AB, BROWN JJ, DAVIES DL, LEVER AF, ROBERTSON JI: Combined captopril and spironolactone treatment in Conn’s syndrome with renal impairment and refractory hypertension. Clin. Endocrinol. (1981) 14:105-108.
   PubMedGoogle Scholar
• STOKES GS, MONAGHAN JC, RYAN M, WOODWARD M: Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism. J. Hypertens. (2001) 19:1161-1165.
   PubMedGoogle Scholar
• OSTER JR, SINGER I, FISHMAN LM: Heparin-induced aldosterone suppression and hyperkalemia. Am. J. Med. (1995) 98:575-586.
   PubMed Web of Science ®Google Scholar